SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-026958
Filing Date
2023-02-07
Accepted
2023-02-07 16:20:32
Documents
14
Period of Report
2023-02-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d399840d8k.htm   iXBRL 8-K 26061
2 EX-99.1 d399840dex991.htm EX-99.1 15959
6 GRAPHIC g399840snap0122.jpg GRAPHIC 9806
  Complete submission text file 0001193125-23-026958.txt   180080

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20230207.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20230207_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20230207_pre.xml EX-101.PRE 10815
8 EXTRACTED XBRL INSTANCE DOCUMENT d399840d8k_htm.xml XML 3236
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 23595362
SIC: 2834 Pharmaceutical Preparations